Pharmacotherapy for Essential Hypertension: A Brief Review

Behnam Heidari, Eleonora Avenatti, Khurram Nasir

Research output: Contribution to journalReview articlepeer-review

Abstract

Hypertension is one of the leading causes of disability-adjusted life years and mortality, with approximately 15% prevalence worldwide. Most patients with hypertension from low- to high-income countries do not receive treatment. Among those who receive treatment, the majority remain undertreated and do not achieve their blood pressure goals. Therefore, new hypertension guidelines introduce more conscientious treatment strategies to maximize the probability of achieving the new strict blood pressure goals compared with the previous guidelines. Who should receive treatment for hypertension? Which antihypertensive medications have the strongest supporting data? Are generic and more affordable medications as effective as expensive brand medications? What are the different treatment strategies to maximize success in controlling blood pressure? Here, we briefly review pharmacotherapy for hypertension and provide answers to these questions as well as some other common questions regarding treatment of hypertension.

Original languageEnglish (US)
Pages (from-to)5-16
Number of pages12
JournalMethodist DeBakey cardiovascular journal
Volume18
Issue number5
DOIs
StatePublished - 2022

Keywords

  • angiotensin converting enzyme inhibitors
  • angiotensin receptor blockers
  • beta blockers
  • calcium channel blockers
  • diuretics
  • essential hypertension
  • pharmacotherapy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Pharmacotherapy for Essential Hypertension: A Brief Review'. Together they form a unique fingerprint.

Cite this